Guest G, Rappaport R, Philippe F, Thibaud E
Arch Fr Pediatr. 1983 Jun-Jul;40(6):453-6.
Dexamethasone has been proposed as therapy of congenital adrenal hyperplasia in adolescents with menstrual abnormalities. Seven patients previously treated with hydrocortisone (mean dosage of 26 mg/m2/day) or prednisone (6 mg/m2/day), received dexamethasone doses between 0.3 and 0.73 mg/m2/day during at least 4 months. Regular menses and satisfactory adrenal suppression were obtained in most cases, but the occurrence of severe striae, sometimes with excessive weight gain, led to the cessation of this treatment. Analysis of data indicate that glucocorticoid activity of dexamethasone is 50-90 times more potent than that of hydrocortisone. Its use, after cessation of growth, should be carefully monitored, starting with much lower doses when necessary.
地塞米松已被提议用于治疗患有月经异常的青少年先天性肾上腺增生。7例先前接受氢化可的松(平均剂量为26mg/m²/天)或泼尼松(6mg/m²/天)治疗的患者,在至少4个月的时间内接受了0.3至0.73mg/m²/天的地塞米松剂量。大多数病例获得了规律月经和满意的肾上腺抑制效果,但严重条纹的出现,有时伴有体重过度增加,导致了该治疗的停止。数据分析表明,地塞米松的糖皮质激素活性比氢化可的松强50 - 90倍。在生长停止后使用时,应仔细监测,必要时从低得多的剂量开始。